Adlai Nortye (ANL) Common Equity (2022 - 2026)
Adlai Nortye (ANL) posted quarterly Common Equity of -$8.3 million for Q4 2025, down 132.65% year-over-year from $25.5 million in Q4 2024, and down 205.06% quarter-over-quarter from $7.9 million in Q2 2025.
Analysis
Adlai Nortye (ANL) Common Equity (2022 - 2026) Analysis & Trends
Adlai Nortye (ANL) has reported Common Equity for 4 consecutive years, with -$8.3 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Common Equity fell 132.65% year-over-year to -$8.3 million; the TTM figure through Dec 2025 stood at -$8.3 million (down 132.65% YoY), while the FY2025 annual figure was -$8.3 million, down 132.65% from the prior year.
- Common Equity declined to -$8.3 million in Q4 2025 per ANL's latest filing, from $7.9 million in the prior quarter.
- Across five years, Common Equity topped out at $75.0 million in Q4 2023 and bottomed at -$241.3 million in Q4 2022.
- Historically, Common Equity has averaged -$24.3 million across 4 years, with a median of $1.8 million in 2024.
- On a YoY basis, Common Equity climbed as much as 281.8% in 2025 and fell as far as 132.65% in 2025.
- Adlai Nortye's Common Equity stood at -$241.3 million in 2022, then surged by 131.1% to $75.0 million in 2023, then plunged by 66.04% to $25.5 million in 2024, then slumped by 132.65% to -$8.3 million in 2025.
- Business Quant data shows ANL's Common Equity at -$8.3 million in Q4 2025, $7.9 million in Q2 2025, and $25.5 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 8.42 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 6.76 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.61 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 5.17 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 9.79 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Adlai Nortye | 500.08 Mn | 268.19 Mn | - | 214.83 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 214.83 Mn |
| Dec 31, 2025 | -8.32 Mn |
| Jun 30, 2025 | 7.92 Mn |
| Dec 31, 2024 | 2,000.00 |
| Jun 30, 2024 | 53.37 Mn |
| Dec 31, 2023 | 75.05 Mn |
| Dec 31, 2022 | -241.29 Mn |